TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32369036
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Cognitive Behavioral Therapy (VR-CBT)
Study: 33894169
Drug: Sevuparin (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevuparin (18 mg/kg per day)
Study: 33894169
Drug: Placebo (NaCl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl, 0.9% solution)
Study: 33738495
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2 IV Q3W, prednisone, G-CSF)
Study: 32356185
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (SOF/DCV-based therapy)
Study: 34381155
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg/24 h for 7 days
Study: 34381155
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg/12 h for 7 days
Study: 35550645
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy (LT)
Study: 35305111
Drug: Human fibrinogen
Normalized name: Human fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human fibrinogen concentrate (70 mg/kg)
Study: 35704027
Drug: 3.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g/day CLA
Study: 32684362
Drug: 3.2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 g/day placebo (sunflower oil)
Study: 35088760
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical acustimulation (TEA) at acupuncture points LI4 and ST36, performed for one hour twice daily for one month.
Study: 32716114
Drug: tivantinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: tivantinib (120 mg bid)
Study: 36078628
Drug: Combined Treatment
Normalized name: POISON IVY/OAK/SUMAC EXTRACTS COMBINED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Treatment (DN + HA)
Study: 36281667
Drug: Icapamespib 10
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 10 mg
Study: 36281667
Drug: Icapamespib 20
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 20 mg
Study: 36281667
Drug: Icapamespib 30
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 30 mg
Study: 36281667
Drug: Icapamespib 20
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 20 mg (multiple ascending dose)
Study: 36281667
Drug: Icapamespib 30
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 30 mg (multiple ascending dose)
Study: 36281667
Drug: Placebo (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (multiple ascending dose)
Study: 36281667
Drug: Icapamespib 30
Normalized name: Icapamespib
DrugBank: Icapamespib (DB18106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib 30 mg (bioavailability)
Study: 36281667
Drug: Icapamespib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icapamespib (oral solution)
Study: 33905405
Drug: Methadone (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.08 mg/kg)
Study: 32969202
Drug: Iberdomide 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.03 mg
Study: 32969202
Drug: Iberdomide 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.1 mg
Study: 32969202
Drug: Iberdomide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.3 mg
Study: 32969202
Drug: Iberdomide 1
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 1 mg
Study: 32969202
Drug: Iberdomide 2
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 2 mg
Study: 32969202
Drug: Iberdomide 4
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 4 mg
Study: 32969202
Drug: Iberdomide 6
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 6 mg
Study: 32969202
Drug: Iberdomide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.3 mg once daily for 14 days
Study: 32969202
Drug: Iberdomide 1
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 1 mg once daily for 28 days
Study: 32969202
Drug: Iberdomide 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.3 mg once daily for 28 days
Study: 32969202
Drug: Iberdomide 1
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 1 mg once daily for 7 days with a 7-day washout, then once daily for 7 more days
Study: 37622634
Drug: Micronized raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized raloxifene 45 mg
Study: 37622634
Drug: Conventional raloxifene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional raloxifene 60 mg
Study: 32674743
Drug: Higher intake
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intake of cruciferous vegetables (>44.6 g/d)
Study: 32674743
Drug: Lower intake
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower intake of cruciferous vegetables (<15.0 g/d)
Study: 34279747
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of pseudoephedrine
Study: 34789230
Drug: Chlorine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorine treatment of water reservoirs
Study: 34789230
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment of water reservoirs
Study: 35091204
Drug: Behavioral cough
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral cough suppression therapy (BCST) plus 6 treatment sessions involving exposure to nebulized capsaicin in progressively larger concentrations (n = 8)
Study: 35091204
Drug: BCST plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCST plus 6 sessions of exposure to a single subthreshold dose of capsaicin (sham; n = 6)
Study: 35240703
Drug: Meditation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meditation group (daily use of a mindfulness‐focused meditation app)
Study: 35588706
Drug: Perspectives app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perspectives app-based cognitive behavioral therapy (CBT) for 12 weeks
Study: 35588706
Drug: Perspectives app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perspectives app-based cognitive behavioral therapy (CBT)
Study: 33769952
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment for 3 years
Study: 36239675
Drug: OTT166 eyedrops
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OTT166 eyedrops (2.5% or 5%) administered BID for 28 days
Study: 33342524
Drug: Packed Promise
Normalized name: pramoxine
DrugBank: Pramocaine (DB09345)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Packed Promise intervention (monthly food boxes with $38 food value and $15 check for fruits and vegetables)
Study: 33661180
Drug: Sham Electroconvulsive
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham Electroconvulsive Therapy
Study: 33661180
Drug: Other Novel
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Novel Therapies
Study: 36060146
Drug: Oral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral allopurinol tablets, 100 mg, 2 times a day
Study: 32975441
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cannabis with 6.7% delta-9-tetrahydrocannabinol (THC)
Study: 36218395
Drug: Rhomboid intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhomboid intercostal and subserratus plane (RISS) block + intravenous patient‐controlled analgesia
Study: 36218395
Drug: Intravenous patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient‐controlled analgesia
Study: 34816917
Drug: Combined doxofylline
Normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined doxofylline and salbutamol treatment for 1 week
Study: 34816917
Drug: Doxofylline treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxofylline treatment for 1 week
Study: 32347591
Drug: High-frequency pulse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency pulse (HFP) TLNS plus physical therapy (PT)
Study: 32347591
Drug: Low-frequency pulse
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency pulse (LFP) TLNS plus physical therapy (PT)
Study: 35436940
Drug: Nimodipine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (60 mg)
Study: 39363095
Drug: Metformin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin therapy
Study: 34864768
Drug: Music Upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music Upper Limb Therapy-Integrated (MULT-I)
Study: 33078636
Drug: Multi-Ingredient Performance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-Ingredient Performance Supplement (MIPS)
Study: 32727613
Drug: PrEP with
Normalized name: Alcohol Prep with Benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP with hydroxychloroquine (400mg daily for 4 days, then 400mg weekly for 6 months)
Study: 38451604
Drug: Opioid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid therapy
Study: 36435233
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with antithrombotic drugs
Study: 33466183
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 24 mg)
Study: 32580752
Drug: Shenhuang granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenhuang granule treatment twice a day for 14 days
Study: 33865841
Drug: 16.25 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16.25 g fiber diet
Study: 33865841
Drug: 32.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32.5 g fiber diet
Study: 32119821
Drug: Shortened mosaic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shortened mosaic HIV‐1 vaccine schedules
Study: 35369762
Drug: Conventional physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physiotherapy (CPT) treatment
Study: 32641343
Drug: Intravenous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous high-dose vitamin C (HIVC) diluted in sterile water for 7 days
Study: 32774912
Drug: Diltiazem (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60 mg)
Study: 32619609
Drug: sprifermin 100
Normalized name: Sprifermin
DrugBank: Sprifermin (DB12616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sprifermin 100 μg q6mo
Study: 33019480
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy combined with multiple drilling and intramedullary drug injection (group EMI)
Study: 33019480
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (group E)
Study: 33019480
Drug: Multiple drilling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drilling combined with intramedullary drug injection (group MI)
Study: 39089652
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation
Study: 32644833
Drug: Low-dose ER-MPH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ER-MPH (0.21 mg/kg equivalent of IR-MPH)
Study: 32644833
Drug: Medium-dose ER-MPH
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose ER-MPH (0.35 mg/kg equivalent of IR-MPH)
Study: 32644833
Drug: High-dose ER-MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ER-MPH (0.48 mg/kg equivalent of IR-MPH)
Study: 33015164
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with antipsychotic medication
Study: 34874836
Drug: Tocilizumab treatment
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab treatment
Study: 32320845
Drug: Tablet-assisted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet-assisted intervention (SPARK) consisting of interactive games and activities to improve provider fidelity and child engagement in evidence-based psychotherapies.
Study: 32233741
Drug: Early antihypertensive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early antihypertensive treatment
Study: 34048504
Drug: PfSPZ-CVac (5.12x10^4)
Normalized name: CVac
DrugBank: CVac (DB17351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-CVac (5.12x10^4) administered via three direct venous inoculations (DVIs) seven days apart
Study: 34048504
Drug: PfSPZ-CVac (1.024x10^5)
Normalized name: CVac
DrugBank: CVac (DB17351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-CVac (1.024x10^5) administered via three direct venous inoculations (DVIs) five days apart
Study: 34048504
Drug: PfSPZ-CVac (5.12x10^4)
Normalized name: CVac
DrugBank: CVac (DB17351)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-CVac (5.12x10^4) administered via three injections five days apart (previous study)
Study: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon-α (peg-IFN-α) add-on treatment
Study: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon-α (peg-IFN-α) switch treatment
Study: 33811250
Drug: Peg-interferon-α (peg-IFN-α)
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon-α (peg-IFN-α) therapy (both add-on and switch)
Study: 34007066
Drug: Low-intensity shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity shockwave therapy (LiST)
Study: 33593287
Drug: Mobile e‐learning,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile e‐learning, mentor‐led online social support networking, and monthly face‐to‐face mentoring support group meetings
Study: 32723294
Drug: HDF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDF group (once and twice weekly HDF)
Study: 32723294
Drug: Twice HDF
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice HDF subgroup
Study: 38176391
Drug: Schema Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schema Therapy (ST)
Study: 34826668
Drug: Dienogest (Visanne)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest (Visanne) 2 mg/day
Study: 34826668
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone)
Study: 33960309
Drug: Spironolactone (1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (1:1 placebo-controlled treatment)
Study: 34511181
Drug: Psychoeducational/behavioral treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational/behavioral treatments
Study: 34511181
Drug: Neuromodulation treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromodulation treatments
Study: 38296290
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate
Study: 32942914
Drug: Daily mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily mobile phone instructional text messages with standard care
Study: 32564438
Drug: Resveratrol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (75 mg twice daily)
Study: 33486869
Drug: High-phosphorus diet
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-phosphorus diet (HPD): 2300 mg/d
Study: 36200646
Drug: High-dose dual-impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual-impregnated antibiotic-loaded cement (DIAC) including gentamicin and clindamycin
Study: 36200646
Drug: Low-dose single-impregnated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose single-impregnated gentamicin antibiotic-loaded cement (SIAC)
Study: 33795330
Drug: Tofacitinib (TOFA)
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib (TOFA) 5mg twice daily
Study: 33905281
Drug: Exposure-Focused Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-Focused Cognitive Behavioral Therapy (EF-CBT)
Study: 33631500
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 mg, orally once daily in the morning)
Study: 33631500
Drug: Placebo (orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally once daily in the morning)
Study: 35268027
Drug: High NO3-
Normalized name: HIGH DENSITY POLYETHYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NO3- (2 × 70 mL beetroot juice/day)
Study: 35268027
Drug: Medium NO3-
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium NO3- (70 mL beetroot juice/day)
Study: 35268027
Drug: Low NO3-
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low NO3- (70 mL beetroot juice on alternate days)
Study: 35268027
Drug: Placebo (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (70 mL of NO3--depleted beetroot juice on alternate days)
Study: 32209983
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester drink ((R)-3-hydroxybutyl (R)-3-hydroxybutyrate, 482 mg/kg body mass)
Study: 33550228
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of high-intensity interval training and time-restricted eating
Study: 34625396
Drug: Educational flyer
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational flyer and monthly HTN education messages for one year (Case group)
Study: 33126100
Drug: Common Elements
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Elements Treatment Approach (CETA) intervention
Study: 39209187
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg once daily
Study: 34224256
Drug: Levothyroxine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine therapy
Study: 32024584
Drug: CPAP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP + Behavioral Sleep Medicine (BSM) intervention targeting physical activity and eating behavior changes
Study: 32536331
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg lorazepam
Study: 33592176
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg daily, with dose reductions to 40 mg and 20 mg allowed)
Study: 33592176
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg, 4 weeks on and 2 weeks off, with dose reductions to 37.5 mg and 25 mg allowed)
Study: 33592176
Drug: Crizotinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (250 mg twice daily, with dose reductions to 200 mg twice daily and 250 mg once daily allowed)
Study: 33592176
Drug: Savolitinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib (600 mg daily, with dose reductions to 400 mg and 200 mg allowed)
Study: 32981068
Drug: Cysteamine cream
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cysteamine cream
Study: 33625939
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of promethazine
Study: 34110605
Drug: secukinumab 150/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 150/300 mg
Study: 33141935
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with immediate provisionalization (Group A: n = 20)
Study: 33141935
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with delayed provisionalization (Group B: n = 20)
Study: 33770684
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg finerenone
Study: 32607644
Drug: LCIG infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LCIG infusion plus three oral doses of placebo
Study: 32607644
Drug: Oral immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immediate-release carbidopa/levodopa (LC-IR)
Study: 33278599
Drug: S-1 (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40-60 mg twice daily for 4 weeks on/2 weeks off for 1 year)
Study: 33278599
Drug: S-1 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 plus oxaliplatin (SOX) (130 mg/m2 every 3 weeks for 6 months)
Study: 33402624
Drug: Minimal excavation
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal excavation and LSTR with triple antibiotic paste (TAP)
Study: 33402624
Drug: Traditional indirect
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional indirect pulp treatment with calcium hydroxide
Study: 33002377
Drug: Leg heat
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leg heat therapy (HT) 3 times/week for 6 weeks using water-circulating trousers at 48°C